To test this, we used FVB mice that naturally mount neu-specific immune responses resulting in complete rejection of neu positive mouse mammary carcinoma (MMC) tumor cells within 3 weeks after challenge [6]. This evidence concerns the gene ERBB2 and neoplasm.